Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

N/A

Waitlist Available

Led By Stephen Ronan, MD

Research Sponsored by Cutera Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 0, 4 weeks, 8 weeks, 16 weeks

Awards & highlights

No Placebo-Only Group

Summary

A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea. Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.

Eligible Conditions

Rosacea
Papulopustular Rosacea

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 0, 4 weeks, 8 weeks, 16 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 0, 4 weeks, 8 weeks, 16 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0, 4 weeks, 8 weeks, 16 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea

Secondary study objectives

Adverse Events

Change in Dermatology Life Quality Index

Comparison of improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea between the treatment arms prior to the 2nd and 3rd treatment, and at 4-6 weeks post-final treatment as assessed using Subject's Comparative Face Assessment Scale.

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: 532nm KTP Laser vs 595nm Pulse Dye LaserExperimental Treatment1 Intervention

This is a single-center prospective, randomized, controlled split-face study in 20 subjects diagnosed with Erythematotelangiectatic Rosacea and/or Papulopustular Rosacea. This two arm, split-face study will consist of: 1. Treatment arm involving treatments with 532nm KTP laser 2. Active control arm involving treatments with 595nm Pulse Dye Laser (PDL) Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

532nm KTP Laser vs 595nm Pulse Dye Laser

2014

N/A

~30

Do I qualify?Apply below to find out